Floatz logo

2-Bromo-?-ergocryptine

PSEN1 Mutation

Kyoto UniversitySmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the PSEN1 Mutation cohort.

Asset / SponsorPhaseRating
Lacosamide
Xiangya Hospital of Central South University
Phase 4BB
Aph-1105
Aphios
Phase 2CCC

Same molecule, other indications

2-Bromo-?-ergocryptine is also rated in:

Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →
prediabetes syndromeDormant
BB
Indicative ·
65 / 100
View asset →
eating disorderDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →